Clinical, microbiological, and salivary biomarker profiles of dental implant patients with type 2 diabetes by Tatarakis, Nikolaos et al.
Nikolaos Tatarakis
Janet S. Kinney
Marita Inglehart
Thomas M. Braun
Charles Shelburne
Niklaus P. Lang
William V. Giannobile
Tae-Ju Oh
Clinical, microbiological, and salivary
biomarker profiles of dental implant
patients with type 2 diabetes
Authors’ affiliations:
Nikolaos Tatarakis, Janet S. Kinney, Marita
Inglehart, Thomas M. Braun, William V.
Giannobile, Tae-Ju Oh, Department of
Periodontics and Oral Medicine, Michigan Center
for Oral Health Research, University of Michigan
School of Dentistry, Ann Arbor, MI, USA
Thomas M. Braun, Department of Biostatistics,
School of Public Health, University of Michigan,
Ann Arbor, MI, USA
Charles Shelburne, Department of Biologic and
Material Sciences, University of Michigan School of
Dentistry, Ann Arbor, MI, USA
Niklaus P. Lang, Department of Oral
Rehabilitation, Faculty of Dentistry, University of
Hong Kong, Hong Kong, China
William V. Giannobile, Department of Biomedical
Engineering, College of Engineering, University of
Michigan, Ann Arbor, MI, USA
Corresponding author:
Tae-Ju Oh, DDS, MS
Department of Periodontics and Oral Medicine
University of Michigan School of Dentistry
1101 N. University Ave
Ann Arbor, MI 48109-1078, USA
Tel.: 734 647 3320
Fax: 734 763 5503
e-mail: taejuoh@umich.edu
Key words: alveolar bone loss, dental implants, diabetes mellitus, microbiology, psychosocial
indicator, salivary diagnostics
Abstract
Objective: Regulators of peri-implant bone loss in patients with diabetes appear to involve
multiple risk factors that have not been clearly elucidated. This study was conducted to explore
putative local etiologic factors on implant bone loss in relation to type 2 diabetes mellitus,
including clinical, microbial, salivary biomarker, and psychosocial factors.
Materials and methods: Thirty-two subjects (divided into type 2 diabetes mellitus and non-diabetic
controls), having at least one functional implant and six teeth, were enrolled in a 1-year
longitudinal investigation. Analyses of clinical measurements and standardized intra-oral
radiographs, saliva and serum biomarkers (via protein arrays for 20 selected markers), and plaque
biofilm (via qPCR for eight periodontal pathogens) were performed at baseline and 1 year. In
addition, the subjects were asked to respond to questionnaires to assess behavioral and
psychosocial variables.
Results: There was a significant increase from baseline to 1 year in the probing depth of implants
in the diabetes group (1.95 mm to 2.35 mm, P = 0.015). The average radiographic bone loss during
the study period marginally increased at dental implants compared to natural teeth over the study
period (0.08 mm vs. 0.05 mm; P = 0.043). The control group harbored higher levels of Treponema
denticola at their teeth at baseline (P = 0.046), and the levels of the pathogen increased
significantly over time around the implants of the same group (P = 0.003). Salivary osteoprotegerin
(OPG) levels were higher in the diabetes group than the control group at baseline only; in
addition, the salivary levels of IL-4, IL-10, and OPG associated with host defense were significantly
reduced in the diabetes group (P = 0.010, P = 0.019, and P = 0.024), while controls showed an
increase in the salivary OPG levels (P = 0.005). For psychosocial factors, there were not many
significant changes over the observation period, except for some findings related to coping
behaviors at baseline.
Conclusions: The study suggests that the clinical, microbiological, salivary biomarker, and
psychosocial profiles of dental implant patients with type 2 diabetes who are under good
metabolic control and regular maintenance care are very similar to those of non-diabetic
individuals. Future studies are warranted to validate the findings in longer-term and larger clinical
trials (ClinicalTrials.gov # NCT00933491).
The application of implant therapy in den-
tistry has offered viable solutions for the
rehabilitation of edentulism, and systematic
reviews have reported high survival rates for
implant-supported restorations in partially
edentulous and well-maintained patients
(Pjetursson et al. 2007; Jung et al. 2008; Tom-
asi et al. 2008). However, the use of implants
is not without complications. Among the
biological complications that can affect
implants after the initial integration phase,
peri-implant diseases hold a key position,
and particularly peri-implantitis is a major
cause of progressive implant bone loss (Lind-
he & Meyle 2008). The prevalence of peri-
implantitis has been reported to range
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between 0 and 14.4% (Berglundh et al. 2002)
and is expected to increase considering the
widespread implementation of implant ther-
apy. Despite the prevalence of the disease,
very limited information is available concern-
ing the local and systemic risk factors that
affect the preservation of peri-implant bone
support. A systematic analysis of the litera-
ture concluded that while a history of peri-
odontitis, poor oral hygiene, and smoking are
strongly associated with peri-implant disease,
there is insufficient evidence with respect to
the effect of diabetes on peri-implant health
(Heitz-Mayfield 2008).
Diabetes mellitus is a metabolic disorder
expressed through different forms. Type 2
diabetes accounts for approximately 90–95%
of the patients with the disease (Association
2011). Epidemiological records indicate that
25.8 million United States citizens have dia-
betes and that about seven million of these
patients remain undiagnosed (US Department
of Health and Human Services 2011). The
global disease burden is also expected to rise
in the future (Wild et al. 2004).
As opposed to the role of diabetes for peri-
implant diseases, substantial evidence exists
to support that diabetes is a true risk factor for
periodontitis, affecting the prevalence, sever-
ity, and the extent of periodontal disease (Loe
1993; Soskolne & Klinger 2001; Taylor 2001;
Mealey & Oates 2006; Taylor & Borgnakke
2008). In the context of a complex, multifacto-
rial disease such as periodontitis, diabetes is
only one of the risk indicators (Genco 1996).
Research also showed that psychosocial fac-
tors such as stress, depression, and certain
types of negative coping behaviors may con-
tribute as putative risk factors for periodontal
deterioration as well (Peruzzo et al. 2007).
Considering the complexities of the patho-
genesis of periodontal disease, single-level
risk assessment models cannot always accu-
rately predict disease progression (Kornman
2008; Offenbacher et al. 2008; Laine et al.
2013). For this reason, multivariate analyses
have been introduced that often combine
clinical and other markers of disease activity
(Lamster et al. 1994; Page et al. 2002; Lang &
Tonetti 2003). Recently, salivary diagnostics
have offered promising panels of biomarkers
for monitoring disease progression (Taba
et al. 2005). Composite risk assessment
incorporating clinical, biochemical (serum
and saliva derived), as well as microbiological
risk factors can characterize patient signa-
tures predicting disease progression or stabil-
ity (Kinney et al. 2011).
In view of the above, this study was
designed to (i) longitudinally evaluate
partially edentulous patients affected by type
2 diabetes mellitus with functional dental
implants to determine clinical and psycho-
social risk factors for progressive alveolar
bone resorption and (ii) evaluate salivary and
serum-derived biomarkers as well as putative
periodontal pathogens for their ability to
predict alveolar bone loss.
Material and methods
Subjects and study design
The investigation was approved by the
University of Michigan Medical Sciences
Institutional Review Board and was registered
with the National Institutes of Health
clinical trials registry (ClinicalTrials.gov:
NCT00933491). Only respondents who gave
their written informed consent and met the
inclusion criteria participated in this project.
The cohort group consisted of subjects, over
40 years of age, who were in good general
health and possessed at least six natural teeth
and at least one implant in function for a
minimum of 6 months. Subjects were
excluded if they were medically unstable and
had any of the following conditions: life
expectancy of <5 years; history of chronic
systemic illness or infection; history of blood
dyscrasias; history of oral cancer or non-
healing lesion; history of cancer treatment
within 12 months; or diagnoses of osteoporo-
sis, osteopenia, or any bone malformations/
defects/diseases. Subjects with active oral
infection such as rampant caries or periodon-
titis as well as pregnant women were also
excluded. Subjects were assigned to either
the type 2 diabetes/test group or non-diabe-
tes/control group. Participants were consid-
ered for the diabetes group if they presented
with a self-reported diagnosis and manage-
ment of type 2 diabetes. The control group
included non-diabetic individuals as deter-
mined by medical history, laboratory test val-
ues, and medical consultation, if needed.
Study timeline and procedures
The baseline visit was completed within
1 month from the screening visit at the
Michigan Center for Oral Health Research
(MCOHR), while a follow-up visit was com-
pleted 12 months after the baseline appoint-
ment. Fig. 1a illustrates the timeline, patient
flow, and the conducted procedures.
Clinical measurements
All teeth except for third molars were exam-
ined for periodontal measures by one of two
non-masked, calibrated examiners (TJO or
NT) during the baseline and follow-up visits.
Clinical parameters including free gingival
margin level (FGM), probing depth (PD), clin-
ical attachment level (CAL), and Bleeding on
Probing (BOP) were measured at six sites per
tooth and implant. Dichotomous scale indi-
ces of plaque accumulation (PI) and exudate
(Exud) were also recorded as previously
described (Haffajee et al. 1983). The measure-
ments were taken with the use of metal and
plastic, 15-mm, calibrated periodontal probes
(PCP-UNC 15, Hu-Friedy Manufacturing Co,
Chicago, IL, USA) for teeth and implants,
respectively. In cases where changes had
occurred between the baseline and the
12-month visit, such as tooth extraction or
replacement of a restoration, the involved
teeth as well as the adjacent surfaces of their
neighboring teeth/implants were excluded
from the analysis.
Standardized radiographs and analysis
Standardized periapical digital radiographs
(Schick Technologies, Long Island City, NY,
USA) were taken in the posterior dentition of
all participants using a parallel technique. In
cases where implants were placed in the
anterior regions of the mouth, standardized
periapical digital radiographs were taken as
well. The radiographs were standardized with
the use of bite registration material and an
aluminum step wedge of known density
(Duckworth et al. 1983) while the same set-
tings were used (63 kV, 8 mA, 0.1 s)
(PLANMECA Intra DC, Helsinki, Finland).
Linear bone measurements were taken on
the mesial and distal surfaces of each tooth
and implant. Reproducible reference points
were used such as the cementoenamel junc-
tion, the apical border of a restoration, or the
implant crown-abutment junction for the
determination of alveolar bone height at
baseline and at 12 months. The radiographs
were taken by one examiner (NT) and were
analyzed by the same trained and calibrated
examiner in a masked, random order with
the use of a computer software measurement
tool (Emago, Oral Diagnostic Systems,
Amsterdam, the Netherlands). In cases where
changes had occurred between the baseline
and the 12-month visit, such as tooth extrac-
tion or replacement of a restoration, the
involved teeth as well as the adjacent sur-
faces of their neighboring teeth/implants
were excluded from the analysis. The same
applied if unrestored implants were identi-
fied.
Serum and saliva biomarkers
Twenty milliliter of whole blood sample was
collected from each subject at the screening
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and 1-year follow-up visit. Once collected,
samples were allowed to clot at room tem-
perature for 30 min and then were centri-
fuged for 15 min at 2600 rpm. Serum was
stored at 80°C until analysis. Likewise,
unstimulated whole saliva was collected at
the baseline and follow-up visit by passive
drooling into sterile plastic tubes from all
participants (Mandel & Wotman 1976). The
collection was completed as soon as 2 ml
whole saliva was collected or 15 min of sam-
pling time had elapsed. Subsequently, the
samples were placed on ice, supplemented
with a proteinase inhibitor combination of
1% aprotinin and 0.5% phenylmethylsulfo-
nylfluoride, and finally aliquoted prior to
storage at 80°C (Ramseier et al. 2009). The
following biomarkers were analyzed for both
the serum and saliva samples: IL-1b, IL-2, IL-
4, IL-6, IL-8, IL-10, TNF-a, INF-c, CRP,
MIP-1a, MIP-1b, MMP-1, MMP-2, MMP-8,
MMP-9, TIMP-1, TIMP-2, osteoprotegerin
(OPG), adiponectin, and procalcitonin
(ProCT). Protein biomarker levels were deter-
mined by a custom human array-based multi-
plex sandwich ELISA system (Quantibody
Custom Array, RayBiotech, Inc, Norcross,
GA, USA), as previously reported (Ramseier
et al. 2009).
Microbial plaque collection and analysis
Subgingival plaque biofilm was harvested
from the mesiobuccal surface of implants
and their adjacent teeth at the baseline and
follow-up visit. The area was dried with a
gentle blast of air and the supragingival/su-
pramucosal plaque was carefully removed. A
sterile Gracey curette was inserted apically
until resistance was felt at the base of the
sulcus/pocket. The operator (TJO or NT) then
initiated one working stroke upward against
the tooth/implant collecting the sample. A
plastic Gracey curette was used for plaque
sampling around implants. The sample was
immediately placed into labeled vials con-
taining 500 ll of stabilizing buffer to prevent
mRNA degradation (RNA ProtectTM, Ambion,
Austin, TX, USA) and was shaken for 10 sec.
The vial was closed and then vortexed for
30 sec. Samples were stored at 4°C until sent
to the laboratory for analysis. The detection
of Aggregatibacter actinomycetemcomitans,
Campylobacter rectus, Fusobacterium nucle-
atum, Prevotella intermedia, Porphyromonas
gingivalis, Tannerella forsythia, T. denticola,
and Candida albicans was evaluated by
qPCR, as previously described (Mullally et al.
2000). The percentage of the total flora for
each species was calculated by dividing the
number of target organisms by the total num-
ber of bacteria as determined by qPCR using
16S rRNA primers that reacted with all bac-
terial species. Data were presented per group
separately for teeth and implants.
Questionnaire for behavioral and psychosocial
factors
A questionnaire was developed to measure
the respondents’ background characteristics
(i.e., gender, age, ethnicity/race, employment
status, educational background, and financial
information) as well as several behavioral
and psychosocial risk factors, such as smok-
ing, alcohol consumption, depression, stress,
and coping styles. To measure depression,
stress, and coping styles, standardized and
validated scales, namely the Center of Epide-
miological Studies Depression Scale (CESD)
(Radloff 1977), the Perceived Stress Scale
(PSS) (Cohen & Williamson 1988), and the
Brief COPE (Carver 1997), were used, respec-
tively.
Examiner training and calibration for clinical and
radiographic measurements
The two clinical examiners (TJO and NT)
completed inter and intraexaminer calibration
sessions held at the beginning of the study
with the participation of a gold standard
examiner (JK). The two examiners demon-
strated at least 83% of CAL measurements
within 1 mm of each other with a 95% confi-
dence interval of (0.74, 0.90) and at least 96%
of PD measurements within 1 mm of each
other with a 95% confidence interval of (0.90,
0.99). The examiner who performed the radio-
graphic analysis (NT) completed inter and int-
raexaminer calibrations sessions held at the
beginning and at the end of the analysis with
the participation of a gold standard examiner.
The interexaminer Pearson’s correlation
coefficient was at least 0.975 with a mean
difference of 0.16 and a 95% confidence inter-
val of 0.05 and 0.27. The intraexaminer
Pearson’s correlation coefficient was at least
0.992 with a mean difference of 0.10 and a
95% confidence interval of 0.04 and 0.16.
Statistical plan and analysis
The clinical, radiographic, biomarker and
microbial data were averaged within each
subject at each time point, separately for
(a)
(b)
Fig. 1. (a) At the screening visit (1 month), participant eligibility was assessed. The baseline visit (0) for the enrolled
subjects was scheduled within 1 month from the screening visit and involved the described study procedures. The
follow-up visit (12 months) was scheduled 12 months after the baseline within a window of 6 weeks. Similar proce-
dures to the baseline appointment were performed with the addition of blood sampling. (b) Thirty-two subjects were
enrolled in the study, 18 in the control group and 14 in the test group. All participants completed the investigation
with the exception of one subject in the diabetes group.
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teeth and implants where available. The bio-
marker data were also log-transformed before
averaging to promote normality. Average val-
ues per group were calculated with their
respective standard errors or deviations. Cate-
gorical data were compared between groups
at each study visit using chi-square tests. For
continuous data, the following comparisons
were performed: (i) comparisons between
groups separately for teeth and implants at
each time point, (ii) comparisons within each
group over time independently for teeth and
implants, and (iii) comparisons of the differ-
ences noted between the average values
around implants and the average values
around natural teeth. Significance of compar-
isons (i) was based upon a two-sample t-test,
and significance of comparisons (ii) and (iii)
was based on a paired t-test and repeated
measures ANOVA for dependent variables.
Repeated measurement MANOVA was used
for the Brief COPE scores. A P-value <0.05
was considered statistically significant. Due
to the exploratory nature of this study, no
adjustment was made to P-values for multi-
ple comparisons. Normality was not calcu-
lated in this study due to the small sample
size of the patient population.
Results
A total of 190 individuals were screened for
eligibility, and 32 subjects were enrolled (18
in the non-diabetes/control group and 14 in
the diabetes type 2/test group). One patient
of the test group did not return for the fol-
low-up visit (Fig. 1b). One patient of the con-
trol group could not provide an adequate
amount of whole saliva for analysis in any of
the study visits. Table 1 presents the back-
ground characteristics of the study groups at
baseline. Nine men and nine women were in
the control group, while seven men and
seven women were in the diabetes group.
The mean ages of the participants were
64  8.1 years for the control and
65  8.9 years for the test group. The groups
differed significantly only at their mean
HbA1C levels (5.7% vs. 7.1%; P = 0.001). The
difference between groups was also signifi-
cant at the 12-month visit. However, no sig-
nificant intragroup changes occurred over the
study period (data not shown).
Table 2 provides an overview of the clinical
data at teeth and implants for both groups.
No statistically significant differences were
noted between the groups both at baseline
and follow-up when teeth and implants were
compared independently. In the diabetes
group only, a significant increase in the mean
PD around implants between the baseline and
follow-up visit was observed (1.95  0.17
mm vs. 2.35  0.18 mm, P = 0.015). There
was a significant trend noted that the mean
PD around implants was statistically
greater than around teeth, both at baseline
(2.01  0.17 mm vs. 1.58  0.07 mm, P
< 0.001) and at 12 months (2.20  0.21 mm vs.
1.53  0.06 mm, P < 0.001) in the control
group and both at baseline (1.95  0.17 mm
vs. 1.62  0.06 mm, P < 0.001) and at 12
months (2.35  0.18 mm vs. 1.56  0.05
mm, P < 0.001) in the test group, respec-
tively. Regarding the mean CAL, the mean
attachment level around implants was higher
than around teeth, both at baseline
(P = 0.002) and follow-up (P = 0.001) visits in
both groups. When bleeding upon probing
was considered, statistically higher scores
were observed around implants compared to
teeth in both groups at both time points
(P < 0.001). In radiographic linear bone levels,
both groups exhibited a statistically signifi-
cant increase around the teeth over the study
period. The mean values at the baseline and
1-year visits were 2.71  0.14 mm and 2.76
 0.14 mm (P = 0.029) for the control group
and 2.59  0.15 mm and 2.65  0.15 mm
(P = 0.004) for the diabetes group, respec-
tively. In the control group, the mean change
(gain) that occurred around implants during
the study visits was significantly different
from the mean change (loss) that occurred
around teeth (0.08  0.12 mm vs. 0.06 
0.03 mm, P = 0.043).
In the biomarker analysis, no major differ-
ences were identified between the two groups
(Table 3, Fig. 2). However, the salivary levels
of IL-4 and IL-10 in the diabetes group
showed a statistically significant reduction at
12 months when compared to the baseline
visit (0.34  0.08 vs. 0.14  0.06 log10 pg/ml,
P = 0.010) and (0.43  0.11 vs. 0.16  0.09
log10 pg/ml, P = 0.019) for IL-4 and IL-10,
respectively. The salivary OPG levels in the
control group revealed a statistically signifi-
cant increase from the baseline to follow-up
(2.59  0.12 vs. 2.87  0.13 log10 pg/ml,
P = 0.005), while in the diabetes group, a sig-
nificant reduction occurred during the study
period (2.92  0.13 vs. 2.79  0.16 log10 pg/
ml, P = 0.024). The two groups also differed
significantly at the baseline level of salivary
OPG, with the diabetes group exhibiting
higher levels than the control group subjects
(2.92  0.13 log10 pg/ml vs. 2.59  0.12
log10 pg/ml; P = 0.050). For serum biomar-
kers, there were no notable findings, except
MMP-1 levels being higher in the control
group than the test group at baseline (data
not shown).
Microbial analysis demonstrated no signifi-
cant differences between the groups both at
the baseline and follow-up, even when teeth
and implants were considered separately
(Table 4). The only exceptions were related
to the levels of T. denticola; at the baseline
visit, higher mean levels of the bacterium
were noted at teeth in the control group as
compared to the diabetes group (0.71  0.12
vs. 0.44  0.06, P = 0.046). Moreover, a
Table 1. Patient demographics
Control Diabetes P-value
Gender
Male 9 7 0.639
Female 9 7
Age (years)
Mean  SD 64  8.1 65  8.9 0.746
Median 66.5 66.5
Range 48–75 51–80
Ethnicity/race
European American 18 11 0.119
African American 0 2
Asian American 0 1
HbA1c (%)
Mean  sd 5.7  0.27 7.1  1.16 0.001
Median 5.7 6.7
Range 5.2–6.2 5.5–9.5
Diabetes duration (years)
Mean  SD NA 9.2  6.9 NA
Median 7.8
Range 1–25
Teeth - Implants
Mean 22.1–2.3 22.6–1.9 0.51
Median 23.0–2.0 25.0–1.5
Range (11–27)–(1–6) (7–27)–(1–6)
SD, standard deviation; NA, not applicable.
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statistically significant increase from the
baseline to the follow-up visit was observed
in the mean levels of T. denticola in the con-
trol group around implant sites (0.45  0.08
vs. 0.78  0.10%, P = 0.003).
The two groups did not differ in their oral
health-related behaviors both at the baseline
and follow-up (Table 5). In the average stress
and depression scores both at baseline and
follow-up appointments, no differences were
noted between the two groups, and no
changes occurred longitudinally as well
within each group (Table 6). Concerning the
patients’ coping styles, the data showed that
the test group scored significantly higher
compared to the control group on the “reli-
gion” coping domain (2.7 vs. 1.8; P = 0.040)
and on the “self-blame” domain (1.8 vs. 1.4;
P = 0.043) at baseline and significantly lower
on the “venting” subscale (1.3 vs. 1.7;
P = 0.049) at follow-up.
Discussion
Despite the high predictability of implant
therapy, little is known regarding the role of
systemic conditions, such as diabetes type 2,
on the long-term prognosis of osseointegrated
implants. To the best of our knowledge, this
feasibility study was the first that attempted
to elucidate differences in the clinical behav-
ior of both implants and teeth in patients
with diabetes type 2, comparing them to
those of non-diabetes controls, in a longitudi-
nal perspective. Moreover, the study explored
the microbiological, proteomic, and psycho-
social profiles of the two groups as potential
explanatory variables for any identified differ-
ences.
The one-year changes in the attachment
levels that characterized the two groups
around their teeth correlate well with the
mean annual rates of disease progression as
noted in other longitudinal studies (Ismail
et al. 1990; Schatzle et al. 2003). Specifically,
in our study, the mean attachment loss for
both groups over the study period was equal
to 0.08 mm, which is very similar to the
0.05 mm mean annual attachment loss found
in a cohort of Norwegians with regular access
to professional dental care over a period of
26 years (Schatzle et al. 2003). When it
comes to radiographic bone changes around
teeth over time, both groups showed a mean
change of 0.06 mm that also corresponds to
the findings of other prospective investiga-
tions (Lavstedt et al. 1986; Norderyd et al.
1999; Paulander et al. 2004). Both groups pre-
sented with a significant increase in the
radiographic bone level between baseline and
follow-up visits. However, this did not
exceed the margin of statistical error and it
was accompanied by similar changes in the
CALs. Interestingly, the diabetes group in
this study did not show significantly higher
disease progression rates as evaluated by
changes in the mean CAL or mean radio-
graphic bone level. This finding contradicts
the results of classic prospective studies con-
Table 2. Clinical and radiographic measures at teeth and implants
Index Group
Teeth Implants
Baseline 12 months D Baseline 12 months D
PD (mm) Control 1.58  0.07 1.53  0.06 0.05  0.06 2.01  0.17b 2.20  0.21b 0.19  0.17
Diabetes 1.62  0.06 1.56  0.05 0.06  0.05 1.95  0.17 b 2.35  0.18 a, b 0.40  0.15
CAL (mm) Control 1.38  0.11 1.46  0.10 0.08  0.06 0.62  0.06 b 0.56  0.06 c 0.06  0.06
Diabetes 1.58  0.20 1.66  0.17 0.08  0.06 0.61  0.07 b 0.67  0.06 b 0.05  0.07
BOP (0/1) Control 0.32  0.03 0.29  0.03 0.03  0.03 0.62  0.06 b 0.56  0.06 b 0.06  0.06
Diabetes 0.25  0.04 0.26  0.04 0.01  0.03 0.52  0.08 b 0.67  0.06 b 0.15  0.08
PI (0/1) Control 0.23  0.03 0.20  0.03 0.03  0.03 0.20  0.06 0.12  0.04 0.08  0.06
Diabetes 0.29  0.05 0.29  0.05 0.00  0.07 0.10  0.04 b 0.13  0.06 0.03  0.07
RBL (mm) Control 2.71  0.14 2.76  0.14 a 0.05  0.03 2.62  0.18 2.54  0.15 0.08  0.12 c
Diabetes 2.59  0.15 2.65  0.15 a 0.06  0.02 2.50  0.19 2.69  0.17 0.19  0.12
Values are means  SEM.
D, Change; PD, probing depth; CAL, clinical attachment level; BOP, Bleeding on Probing; PI, Plaque Index; RBL, radiographic bone level; SE, standard error.
aSignificant difference within group over time (P < 0.05).
bSignificant difference between teeth and implants within group at same visit (P < 0.05).
cSignificant difference between the changes that occurred within the control group over time when teeth and implants were compared (P < 0.05).
Table 3. Salivary protein biomarkers for diabetic and control patients
Biomarker
log10(pg/ml) Group Baseline 12 months
IL-2 Control 1.31  0.21 1.06  0.22
Diabetes 0.76  0.22 0.85  0.28
IL-6 Control 1.42  0.18 1.41  0.18
Diabetes 1.41  0.18 1.21  0.25
IL-8 Control 3.20  0.03 3.21  0.04
Diabetes 3.24  0.05 3.17  0.07
TNF-a Control 1.68  0.24 1.89  0.13
Diabetes 1.24  0.31 1.44  0.28
ΙNF-c Control 1.05  0.16 0.92  0.20
Diabetes 0.93  0.18 0.69  0.23
CRP Control 3.01  0.29 2.82  0.30
Diabetes 2.93  0.32 2.99  0.30
MIP-1a Control 2.74  0.20 2.81  0.15
Diabetes 2.85  0.28 2.71  0.30
MIP-1b Control 0.86  0.11 0.83  0.10
Diabetes 0.81  0.13 0.88  0.15
MMP-1 Control 3.95  0.15 4.07  0.11
Diabetes 4.01  0.11 4.09  0.17
MMP-2 Control 2.70  0.16 2.51  0.23
Diabetes 2.24  0.24 1.94  0.39
MMP-9 Control 4.26  0.04 4.29  0.04
Diabetes 4.32  0.05 4.24  0.07
TIMP-2 Control 3.90  0.02 3.88  0.03
Diabetes 3.92  0.04 3.90  0.06
ProCT Control 0.88  0.23 1.08  0.20
Diabetes 1.33  0.23 0.94  0.25
Values are means  SE: standard error.
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ducted in diabetic populations in which the
diabetic individuals presented with higher
levels of attachment and bone loss compared
to their healthy counterparts (Nelson et al.
1990; Novaes et al. 1996; Taylor et al. 1998).
However, certain aspects differentiate our
study from the aforementioned inves-
tigations. Firstly, the previous studies were
performed in populations with higher levels
of periodontal disease at baseline and fol-
lowed a model of untreated, natural disease
progression during the observation period,
while in our study, the subjects were peri-
odontally stable and received prophylaxis at
least twice, as required by the study protocol.
Secondly, the level of diabetes control in our
sample could be regarded as good given that
the mean HbA1C level was approximately
7.0% and did not change during the study
period. In fact, only three subjects at screen-
ing and two subjects at 12 months presented
with a value higher than 8%. It has been pos-
tulated that metabolic control correlates with
periodontal health status (Taylor & Borg-
nakke 2008).
The comparison of the two groups in peri-
implant changes failed to identify significant
differences as well. The mean PD of diabetic
subjects around implants increased signifi-
cantly between the two visits; however, this
change was not followed by significant altera-
tions in the attachment or radiographic bone
levels. Considering that no differences
existed around teeth, as explained above, this
appears to be a biologically acceptable find-
ing. In the same vein, there is no other report
indicating certain differences in the mean
annual bone changes around implants of
diabetic and non-diabetic patients. Tawil
et al. (2008) did not find any significant
differences in the mean peri-implant bone
loss between diabetic and non-diabetic
subjects after following them for a period of
1–12 years. The latter investigation is relevant
because it included type 2 diabetes patients
with mainly good and fairly good control
(mean HbA1C = 7.2%) under regular mainte-
nance, a profile that is very similar to our
study population. Besides, the importance of
periodontal maintenance for the stability of
peri-implant tissues was confirmed by a
5-year follow-up study that showed that the
absence of preventive maintenance in individ-
uals with pre-existing peri-implant mucositis
was associated with a high incidence of peri-
implantitis (Costa et al. 2012).
When evaluating the salivary proteomic
profiles of the two groups, there were signifi-
cantly higher salivary OPG levels in the test
group at baseline. Costa and associates have
reported higher salivary OPG levels in diabet-
ics, irrespective of their periodontal status
when compared to non-diabetic controls
(Costa et al. 2010). This may be in line with
the finding that increased concentrations
have been also identified in the serum of dia-
betic individuals (O’Sullivan et al. 2010). The
hypothesis that has been proposed is that
Fig. 2. Levels of selected salivary biomarkers over the study period. The levels of IL-4, IL-10, and OPG were signifi-
cantly (*) reduced between baseline and follow-up visits in the diabetes group (P < 0.05); on the other hand, the lev-
els of OPG were significantly (*) increased from the baseline to the follow-up visit in the control group (P < 0.05).
The levels of OPG were significantly (**) different between groups at baseline (P < 0.05).
Table 4. Pathogens identified at tooth and implant sites in diabetic and control patients
Species Group
Teeth only Implants only
Baseline 12 months Baseline 12 months
T.f. (%) Control 1.24  0.21 1.99  0.36 1.56  0.28 1.62  0.31
Diabetes 1.25  0.14 1.24  0.26 1.62  0.37 1.61  0.24
T.d. (%) Control 0.71  0.12a 0.73  0.09 0.45  0.08 0.78  0.10b
Diabetes 0.44  0.06 0.62  0.10 0.45  0.10 0.54  0.09
P.g. (%) Control 0.88  0.13 0.82  0.09 0.81  0.10 0.98  0.09
Diabetes 0.76  0.09 0.87  0.17 0.57  0.12 0.76  0.11
C.r. (%) Control 1.85  0.37 1.38  0.19 1.67  0.39 1.51  0.30
Diabetes 1.30  0.33 1.82  0.41 1.67  0.33 1.20  0.35
F.n. (%) Control 2.21  0.32 2.17  0.28 2.33  0.35 2.46  0.53
Diabetes 2.12  0.30 2.43  0.49 2.26  0.40 2.04  0.41
P.i. (%) Control 1.87  0.25 1.54  0.18 1.66  0.25 1.87  0.19
Diabetes 1.31  0.15 1.67  0.24 1.51  0.27 1.55  0.29
A.a. (%) Control 1.64  0.18 1.76  0.16 1.65  0.15 1.71  0.19
Diabetes 1.40  0.14 1.78  0.20 1.33  0.12 1.38  0.15
C.a. (%) Control 1.69  0.18 1.74  0.17 1.63  0.16 1.80  0.24
Diabetes 1.60  0.21 1.73  0.22 1.53  0.18 1.70  0.26
Values are means  SE: standard error; T.f., Tannerella forsythia; T.d., Treponema denticola; P.g.,
Porphyromonas gingivalis; C.r., Campylobacter rectus; F.n., Fusobacterium nucleatum; P.i., Prevotella
intermedia; A.a., Aggregatibacter actinomycetemcomitans; C.a., Candida albicans
aSignificant difference between groups at baseline (P < 0.05).
bSignificant difference within group over time (P < 0.05).
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OPG is released by the vascular system as a
putative compensatory mechanism to
prevent further vascular damage or is alterna-
tively induced by other inflammatory mecha-
nisms and mediators (Schoppet et al. 2003).
When analyzing the proteomic markers
within each group between the two time
points, it was observed that some significant
changes took place. The mean levels of OPG
in the diabetes group were reduced both at
whole saliva and at serum. The opposite
occurred in the control group, where a signif-
icant increase was noted in the whole saliva
levels. The above changes are difficult to
justify biologically taking into account the
metabolic status of the groups solely, as the
latter did not change significantly over time.
However, we have to acknowledge that the
observed changes were based on two time
points; therefore, we could not detect the
fluctuations that might have taken place dur-
ing the whole year. Similarly, it appeared
that the salivary levels of IL-4 and IL-10 of
the diabetes group and the serum levels of
the IL-10 in the control group were reduced
significantly over time. Considering that the
clinical and metabolic status of the groups
remained unchanged during the study period,
we can only speculate that other factors such
as the ones described above are responsible
for this effect.
In microbiological aspects, no major differ-
ences were noted either between the groups
or within the groups at the two study visits.
This is not surprising because previous inves-
tigations have reported similar findings (Col-
lin et al. 1998; Yuan et al. 2001). In the study
by Yuan et al., certain species (A. actinomy-
cetemcomitans, P. gingivalis, E. corrodens,
T. denticola, and C. albicans) were detected
in a sample of 246 healthy and diabetes type
2 adults with the use of PCR. Both healthy
and diseased sites were sampled, and the
results demonstrated that the prevalence of
the above pathogens was similar in both
groups. In our study, the subjects had stable
periodontal and peri-implant health, with the
majority of the sites being shallow as
reflected by the recorded clinical measures.
The sampled sites both around teeth and
implants harbored typical pathogens. How-
ever, diabetes did not appear to be an impor-
tant modifying factor. This finding can be
attributed to the fact that all participants
were receiving regular dental care with peri-
odontal prophylaxis at least twice during the
study period. Our study is the first to report
that the subgingival peri-implant flora of
well-maintained, type 2 diabetic subjects
does not contain higher concentrations of
certain pathogens compared to non-diabetic
individuals. The study also confirmed that in
partially edentulous patients, the microbial
ecology does not majorly differ between teeth
and implants, a finding that has been docu-
mented in the literature (Leonhardt et al.
1993; Oringer et al. 1998; van Winkelhoff
et al. 2000). Interestingly, the control group
Table 5. Behavioral factors in diabetic and control patients (mean)
Behavioral responses
Control Diabetes
P (time)
P (t 9 d)
Baseline
Follow-up
Baseline
Follow-up
How often do you brush your teeth?* 4.67
4.50
4.54
4.38
0.22
0.96
How often do you floss your teeth?* 3.78
3.83
3.23
3.23
0.88
0.88
How often do you drink alcohol?* 2.28
2.33
2.31
2.31
0.83
0.83
Do you smoke? P-value
Yes (Baseline) 1 2 0.40
Cigarettes 1 2
Cigars 0 0
Yes (12 months) 1 0 0.58
Cigarettes 0 0
Cigars 1 0
t 9 d, time 9 diabetes (effect of time on diabetes status).
*The answers were given on a scale with 1 = Never, 2 = once a month, 3 = once a week, 4 = more
than once a week, and 5 = every day.
Table 6. Psychosocial factors in diabetic and control patients
Control Diabetes
Baseline (Mean  SD)
Follow-up (Mean  SD)
Baseline (Mean  SD)
Follow-up (Mean  SD)
PSS* 2.0  0.48
2.1  0.27
2.0  0.37
2.3  0.60
CESD† 1.2  0.26
1.3  0.26
1.3  0.27
1.3  0.22
Brief COPE‡
Self-distraction 1.9  1.01
1.7  0.71
1.6  0.49
1.8  0.88
Active coping 2.3  0.97
2.6  0.87
2.3  1.01
2.5  0.96
Denial 1.3  0.67
1.1  0.27
1.2  0.37
1.2  0.22
Substance use 1.1  0.37
1.1  0.37
1.1  0.29
1.0  0.00
Use of emotional support 2.0  1.0
2.0  0.92
2.3  0.99
2.2  0.69
Use of instrumental support 1.8  0.96
1.8  0.96
2.0  0.87
2.0  0.87
Behavioral disengagement 1.5  1.43
1.2  0.49
1.4  0.66
1.1  0.28
Venting 1.8  0.91
1.7  0.55
1.8  0.64
a1.3  0.43
ositive reframing 2.4  1.06
2.3  0.96
2.6  1.04
2.2  0.85
Planning 2.3  1.20
2.3  1.05
2.3  0.77
2.3  1.16
Humor 2.2  1.13
2.0  1.04
1.6  0.77
1.4  0.68
Acceptance 2.1  0.93
2.2  0.97
2.7  1.17
2.3  0.99
Religion 1.8  1.06
2.1  1.0
a2.7  1.19
b2.3  1.10
Self-blame 1.4  0.51
1.5  0.66
a1.8  0.72
1.8  0.78
SD: standard deviation; repeated measurement ANOVAs used for the dependent variables PSS and
CESD, and repeated measurement MANOVA for the Brief COPE scores.
*The answers range from 1 = never to 5 = always.
†The answers range from 1 = hardly ever, 2 = some of the time, and 3 = most of the time.
‡The answers range from 1 = I haven’t been doing this at all, 2 = a little, 3 = medium amount, and
4 = a lot.
aSignificant difference between groups (P < 0.05).
bSignificant difference within group over time (P < 0.05).
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harbored higher levels of T. denticola around
their teeth at baseline, and the levels of the
pathogen increased significantly over time
around the implants of the same group. Yet,
the above findings cannot be related to any
specific clinical changes that occurred during
the study period as no disease progression
took place in the control group.
When comparing the two groups with
regard to their stress and depression scores,
no significant differences were observed at
any of the time points or during the study
period. A meta-analysis reported that the
prevalence of depression was significantly
higher in patients with type 2 diabetes com-
pared with those without [17.6 vs. 9.8%,
OR = 1.6, 95%, confidence interval (CI)
1.2–2.0] (Ali et al. 2006). In fact, two out of
the ten included studies applied the same
instrument that we used and confirmed the
effect. However, we have to note that the
meta-analysis was based on cross-sectional
studies only. Therefore, causality could not
be implied. In addition, several confounding
factors may have influenced the effect. A
study examining the relationship between
diabetes and depressive symptoms assessed
through CESD in a large, racially diverse
cohort in the United States found that
demographics, lifestyle behaviors, antidepres-
sant use, and BMI were actually more
strongly associated with depressive symp-
toms than having a diabetes diagnosis
(Osborn et al. 2011).
The two study groups differed in specific
domains of coping strategies; the test group
used a combination of problem-based and
emotional-based strategies namely, religion
and self-blame to a greater extent when cop-
ing with daily strains compared to the con-
trol group at baseline. Interestingly, over
time the diabetes group responded with a
significant reduction in the religion-based
coping style score. At the follow-up appoint-
ment, the control group demonstrated a
higher ability based on the responses to cope
with their strains by venting compared to
the diabetes group. Overall, both groups used
problem-based strategies most strongly such
as positive reframing, active coping, plan-
ning, religion, acceptance, and humor. This
finding is consistent with the findings of a
study that was conducted with diabetic
patients in Turkey (Tuncay et al. 2008).
Moreover, the total mean scores for the dif-
ferent domains in both groups appear to be
low, indicating that the participants were
not dealing with significant stressful life
events.
We believe that there are several limita-
tions and strengths in our study. Similar to
other hypothesis-generating studies, it has
limited power to fully address any of the
investigated outcomes. Even though the two
groups appear to be statistically balanced at
baseline, we encountered challenges in the
recruitment of patients with diabetes, which
led to a discrepancy in the number of partic-
ipants in the two groups. Moreover, we per-
formed analyses based on two time points
only over a one-year period. Despite most
longitudinal studies are based on annual or
biannual examinations, there is a possibility
that we could not identify some of the epi-
sodic effects of diabetes, considering that
fluctuations of metabolic control are not
uncommon. The same applies to the proteo-
mic and microbial data. Even though the
harvesting techniques for saliva and serum
were standardized, it has been reported that
many factors can influence the biomarker
concentration, such as the time of collec-
tion, hormonal circadian rhythms, diet,
smoking, and medications. Moreover, the
type of implant design and surface, the type
of surgery, and technical aspects of the su-
prastructure could not be standardized
because of the nature of the study. The
impact of the above on implant bone loss
has been suggested, known to take place
mainly during the first 6 months to 1 year
of function. To minimize the role of this
modifier, only functional implants of
6 months or more were included in the
study. All implants but one were in function
for more than 1 year (data not shown). An
aspect that may have implications for the
generalizability of our study results relates
to the profile of our diabetes population. For
the most part, the participants were well
controlled and compliant with their dental
appointments, belonged to a specific age
range, and were partially edentulous. Our
study presents with certain strengths; to the
best of our knowledge, this was the first
investigation designed in a prospective
manner with specific criteria evaluating the
effect of diabetes both on teeth and
implants. It also offered the opportunity to
elucidate whether the presence of disease
modified the response of teeth and implants
differently within the same host. The
selected methodology was very comprehen-
sive permitting a multivariate assessment
and comparison of the two groups in terms
of their clinical, microbial, proteomic,
behavioral, and psychosocial profiles. The
complexity of periodontal and peri-implant
bone loss is not fully understood. This
study differs from previous investigations
that focused only on crude endpoints, such
as implant loss. Salivary diagnostics is an
emerging field and holds a potential in the
risk assessment of oral bone loss, especially
in patients with systemic implications,
such as diabetes. In addition, the role of
psychosocial measures was analyzed for the
first time in diabetic individuals with
dental implants. The applied methods have
been previously validated and offer a
standardized way to evaluate the groups
longitudinally.
In conclusion, the study results suggest
that the clinical, microbiological, salivary
biomarker and psychosocial profiles of dental
implant patients with type 2 diabetes who
are under good metabolic control and regular
maintenance care are very similar to those of
non-diabetic individuals. Future studies are
warranted to validate the findings in longer-
term and larger clinical trials.
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